Under the agreement, the companies will jointly work for providing drug discovery platform to their existing and new clients to identify and develop new therapeutics targeting CNS disorder.
The financial terms of the agreement are not been disclosed.
Evotec chief operating officer Mario Polywka said by bringing together the CNS drug discovery platforms of Evotec and PsychoGenics, their clients and partners will benefit through an increased probability of success and faster and more informed decision making in their drug discovery efforts with the goal of delivering pre-clinical candidates in the most time and cost efficient manner.